C&D to initiate trial of its Trojan Vibrations line across several urban markets
PRINCETON, N.J. — Church & Dwight will be initiating trial of its Trojan Vibrations personal massagers with a multi-city giveaway, the company announced Wednesday. Beginning in Washington on Nov. 13, Church & Dwight will feature its latest product innovations via a specially-designed Trojan Vibrations Pleasure Carts that are modeled after traditional hot dog carts.
"With the success of the Trojan vibrator giveaway in New York City, it is evident that Americans understand that pleasure is a normal part of sexually healthy lives," stated Bruce Weiss, VP marketing, Trojan sexual health. "By innovating high-quality vibrators and making them easily accessible on drug store, mass merchandiser and grocery store shelves, Trojan remains dedicated to taking pleasure out of the bedroom and into the mainstream."
People can track the tour and uncover upcoming stops by visiting Facebook.com/TrojanVibrations.
Acura Pharmaceuticals moves forward with plans to launch diversion-hindering PSE product
PALATINE, Ill. — Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that it inhibits the diversion to methamphetamnine.
We have begun executing a plan to generate awareness of Nexafed with pharmacists to support stocking of Nexafed in the pharmacies and generate consumer recommendations by the pharmacists," Acura president and CEO Bob Jones told analysts Wednesday morning. "We have met numerous independent pharmacists from several states at recent trade shows, and have found an enthusiastic level of interest in Nexafed. These pharmacists appear pleased that we intend to offer Nexafed at a price comparable to similar branded products."
Nexafed will still fall under sales restriction dictated by the Combat Methamphetamine Epidemic Act of 2006, which requires all pseudoephedrine products to be placed behind the pharmacy counter, Jones noted, as well as more stringent state restrictions where applicable. Both Oregon and Mississippi require a prescription for any PSE-containing products, for example.
"Our long-term objective is really twofold. One is to continue to improve upon our technology, which we believe we can do," Jones said. The second long-term objective would be to demonstrate real, practical experience in the marketplace relative to disrupting meth production, Jones added. Following that, Acura would then be to make applications either to individual states or to the Drug Enforcement Agency in an effort to get exemptions from relative sales restrictions.
"We look at the independent pharmacies as being the early adopters," Jones said. "We think if we establish the product with independent pharmacists, that will demonstrate to the chains [the benefits of Nexafed]."
According to the company, Nexafed will be the first marketed product utilizing Acura’s proprietary Impede technology, and expects to make its first shipments in December.
Perrigo chief: Store brands big driver behind OTC growth, prepping launch of Mucinex equivalent
ALLEGAN. Mich. — Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer’s first-quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows. "What we are seeing though, is the continued acceleration of store brand as being the reason why we’re seeing the growth in our OTC category. For us to have a 9.4% growth in our OTC category, we think is a strong indication," Papa said.
Sales of cough-cold products could become a big driver behind improved OTC sales overall, especially as sales comparisons are placed against the significantly slow season last year. "While it is too early in the cough/cold/flu season to make too many comments, it appears to be tracking along a normal trend," Papa said.
Perrigo is currently prepping the launch of the store-brand version of Mucinex 600 mg, which had annual branded sales of approximately $135 million, Papa said. "We are in the process of validating additional batches of Guaifenesin ER 600 mg and continue to expect the launch of this product during our current fiscal year," he said, adding that additional as-yet-to-be-named products within that brand family will be introduced as well.
Perrigo also is gearing for a possible store-brand equivalent of Pfizer’s Nexium proton-pump inhibitor, which is expected to switch from prescription-only to over-the-counter. "We’ve stated that we believe there’s over $10 billion of new product that will move from prescription to OTC over the next five years," Papa said. "Obviously, Nexium is one of the largest of those products." Pfizer recently applied for a three-year OTC exclusivity on the switch, Papa reported. "As to whether or not they will get a three-year exclusivity right now, I would say that the operating assumption is most proton-pump inhibitors have received a three-year exclusivity as they have switched from prescription to OTC status. However, in this case, that product … already has a frequent heartburn indication," he said. "We’ll have to wait and see what the [Food and Drug Administration] decides on that question."
Perrigo is making a big move into the pet care business with its recent acquisition of Sergeant’s Pet Care. "The integration of their broad attractive portfolio of pet care products adds a new category to our consumer healthcare segment," Papa said. "We are pleased to add over 1,000 SKUs that Sergeant’s has in its broad portfolio of products, bringing Perrigo’s total number of SKUs to approximately 15,000 SKUs."
The most attractive new product expected to come out of its Sergeant’s Pet Care facilities is a new store-brand version to the Frontline product family, which has branded sales of more than $500 million in the U.S. market. "These are expensive products that can truly benefit from the addition of a quality, affordable, store-brand offering," Papa said.
Perrigo’s consumer healthcare segment net sales increased 9% to $450 million for the quarter ended Sept. 29 due to an increase in sales of existing products of $36 million (contract, cough-cold and smoking-cessation categories), new product sales of $13 million (gastrointestinal, cough-cold and dermatological categories) and $9 million in incremental sales attributable to the acquisition of CanAm. These combined increases were partially offset by a decline of $17 million in sales of existing products (e.g., analgesics and feminine hygiene categories) and a decline of $4 million due to discontinued products.
The nutritionals segment reported first-quarter net sales of $103 million, compared with $120 million a year ago as existing product sales declined $20 million, partially offset by new product sales of $3 million (infant formula category). The decrease in sales was due primarily to a decline in existing product sales in the vitamin, minerals and dietary supplements category driven by increased competition and increased retail shipments of infant formula placed in the fourth quarter of fiscal 2012 in advance of the planned July 1 shutdown of the Perrigo’s Vermont plant to prepare for the installation of a new packaging line.